SAREPTA THERAPEUTICS, INC. Available-for-sale Securities, Gross Unrealized Loss
SAREPTA THERAPEUTICS, INC. (SRPT) reported Available-for-sale Securities, Gross Unrealized Loss of $2.00 thousand for the 9-month period ending 2015-09-30, per its 10-Q filed 2015-11-05.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss · last filed 2015-11-05
- SAREPTA THERAPEUTICS, INC. available-for-sale securities, gross unrealized loss for the quarter ending 2015-09-30 was -$17.00K.
- SAREPTA THERAPEUTICS, INC. available-for-sale securities, gross unrealized loss for the quarter ending 2015-06-30 was $2.00K.
- SAREPTA THERAPEUTICS, INC. available-for-sale securities, gross unrealized loss for the quarter ending 2015-03-31 was $17.00K.
- SAREPTA THERAPEUTICS, INC. available-for-sale securities, gross unrealized loss for the quarter ending 2014-12-31 was $39.00K.
| Period end | Available-for-sale Securities, Gross Unrealized Loss 3 month | Available-for-sale Securities, Gross Unrealized Loss 6 month | Available-for-sale Securities, Gross Unrealized Loss 9 month | Available-for-sale Securities, Gross Unrealized Loss 12 month |
|---|---|---|---|---|
| 2015-09-30 | -$17.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | -$15.00K derived: sum of 2 quarters · filed 2015-11-05 | $2.00K 10-Q · filed 2015-11-05 | $41.00K derived: sum of 4 quarters · filed 2015-11-05 |
| 2015-06-30 | $2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $19.00K 10-Q · filed 2015-08-06 | $58.00K derived: sum of 3 quarters · filed 2015-11-05 | |
| 2015-03-31 | $17.00K 10-Q · filed 2015-05-07 | $56.00K derived: sum of 2 quarters · filed 2015-11-05 | ||
| 2014-12-31 | $39.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2015-11-05 | $95.00K 10-Q · filed 2015-11-05 | ||
| 2014-09-30 | $56.00K 10-Q · filed 2014-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |